NCT00239707View on ClinicalTrials.gov

GIP: Glucose-dependent Insulinotropic Peptide

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions
Type 2 Diabetes
Interventions
DRUG

GIP

One-time 20 ng/kg/min infusion over 3 hours

DRUG

Modified GIP

One-time infusion over 3 hours; dose to maintain desired biological effect of below 140 mg/dl

DRUG

Normal Saline

one-time infusion over 3 hours

Trial Locations (1)

21225

National Institute on Aging, Clinical Research Branch, Baltimore

All Listed Sponsors
lead

National Institute on Aging (NIA)

NIH

NCT00239707 - GIP: Glucose-dependent Insulinotropic Peptide | Biotech Hunter | Biotech Hunter